Delft Imaging
Share:
Overview of innovation

RetCAD is a class IIa CE-certified software product using Artificial Intelligence that analyses colour fundus images for the presence of Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR), and glaucoma with the newest version. The performance of RetCAD is at the same level as trained certified graders. This means reduced workload for eye-care specialists, which in return can spend more time on e.g. reading abnormal images.

With today’s digital colour fundus cameras, one or multiple images can be acquired from a patient within seconds and are presented on the operator’s computer screen. RetCAD will automatically start analysing any acquired colour fundus image and provide the user with a score and heat map that indicate referable Age-related Macular Degeneration and/or Diabetic Retinopathy.

Patients with signs of Age-related Macular Degeneration or Diabetic Retinopathy are instantly identified. These patients require follow-up by an eye-care specialist. Patients with no signs of Age-related Macular Degeneration or Diabetic Retinopathy do not require follow-up and are advised to have an eye examination again in one or two years.

Type of Intellectual Property protection
Registerable IP
Innovation Opportunity Type
Collaboration
Partnership
Research
Sales
Industry
​Information and communication
Cloud Computing
Human health and social work activities
Medical Devices
HighTech
Health Technologies
Diagnostics
Technology Readiness Level
TRL 9 – Being utilized by the end user
Co-creators
Thirona
Website link
https://www.delft.care/retcad/